Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study

PURPOSE: The immune checkpoint inhibitor is approved for breast cancer treatment, but the low expression of PD-L1 limits the immunotherapy. CD155 is another immune checkpoint protein in cancers and interacts with ligands to regulate immune microenvironment. This study is aimed at investigating the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yu-Chen, Zhou, Quan, Song, Qing-Kun, Wang, Rui-Bin, Lyu, Shuzhen, Guan, Xiudong, Zhao, Yan-Jie, Wu, Jiang-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201814/
https://www.ncbi.nlm.nih.gov/pubmed/32411795
http://dx.doi.org/10.1155/2020/3948928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201814/
https://www.ncbi.nlm.nih.gov/pubmed/32411795
http://dx.doi.org/10.1155/2020/3948928

Ejemplares similares